Preparation method and application of gold-silver alloy targeted liver cancer nano-drug delivery system based on thermal therapy, photodynamic therapy and gas therapy

By adopting a gold-silver alloy nanodrug delivery system in the treatment of hepatocellular carcinoma, combined with thermal therapy, photodynamics and gas treatment, the problems of poor efficacy and drug resistance of existing treatment methods are solved, and a highly efficient and targeted multi-mode has been achieved. Treatment effect.

CN118903470APending Publication Date: 2024-11-08HENAN UNIVERSITY
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411142744.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing hepatocellular carcinoma treatment methods have side effects, low bioavailability and poor efficacy. A single treatment method is difficult to effectively inhibit tumors and is prone to lead to drug resistance and recurrence.

Method used

The gold and silver alloy targeted liver cancer nanodrug delivery system based on thermal therapy, photodynamic therapy and gas therapy is adopted, and the targeted polypeptide 9R-P is used as a carrier. GNC is used as a carrier, and the photosensitizer ICG and gas diagnostic agent L-arg are internally modified, and the targeted polypeptide 9R-P is externally modified. Achieve the synergistic effect of photothermal, photodynamic and gas treatment, and accurately target liver cancer cells.

Benefits of technology

Multimodal combined treatment has been achieved, which has improved the therapeutic effect of liver cancer, enhanced the targeting and biosafety of the drug, reduced side effects, and improved efficacy and biocompatibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention relates to a preparation method and application of a targeted gold-silver alloy nano-drug delivery system based on thermal therapy, photodynamic therapy and gas therapy. According to the system, a gold nanocage (GNC) is used as a carrier, a photosensitizer indocyanine green (ICG) and a gas diagnosis and treatment reagent L-arginine (L-arg) are loaded, finally, polypeptide 9R-P201 is modified on the outer layer to serve as a targeting agent, and the targeted liver cancer nanometer diagnosis and treatment reagent GNC (at) ICG / L-arg (at) 9R-P (GIL9R) integrating gas treatment, photodynamic treatment and photothermal treatment is formed. In short, GNC, as a good photo-thermal material, plays an important role in photo-thermal therapy; a photosensitizer ICG and a gas diagnosis and treatment reagent L-arg are loaded into the GNC, and the ICG generates reactive oxygen species (ROS) under light stimulation to oxidize the L-arg to generate NO, so that the growth of tumor cells is effectively inhibited; and finally, 9R-P201 of which the outer layer is modified with active targeting liver cancer cells delivers the nano delivery system to a tumor site. And finally, the combined targeting of photothermal, photodynamic and gas treatment on liver cancer is realized, so that a more efficient treatment effect is realized.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine and health technology, and specifically relates to a preparation method and application of a gold-silver alloy nanodrug delivery system targeting liver cancer based on thermal therapy, photodynamic therapy and gas therapy. Background Art

[0002] Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, and the incidence of liver cancer is reported to be increasing worldwide. Generally speaking, the 5-year survival rate of HCC patients is less than 15%, but conventional treatments such as surgery, radiotherapy, and chemotherapy have limitations such as side effects, low bioavailability, and poor efficacy. Therefore, there is still an urgent need to seek more effective treatments.

[0003] Gold nanocages (GNCs) have a hollow interior and higher anticancer drug loading capacity, higher photothermal conversion efficiency, tunable localized surface plasmon resonance (LSPR) band in the near-infrared region, and excellent biocompatibility, making them ideal carriers for controlled drug release. Therefore, they can be used as excellent photothermal agents and the loaded drugs can be precisely released to specific tumor tissues through controllable stimulation.

[0004] Indocyanine green (ICG) is a medical contrast agent approved for intravenous administration. Under near-infrared laser irradiation, ICG can produce significant cytotoxic ROS. Due to the nature of ICG's easy aggregation in the body and its rapid clearance from the body, its ability to be used in PDT or fluorescence imaging is seriously compromised. In order to improve the stability of ICG under solution conditions, many nanocarriers for encapsulating ICG have been studied, including calcium phosphate derivatives, mesoporous silica nanoparticles, and polymer nanocomposites, which greatly improve the application range and therapeutic effect of ICG.

[0005] FoxM1 belongs to the forkhead box (Fox) protein superfamily and is a typical proliferation-related transcription factor. FoxM1 is basically absent in quiescent or differentiated cells. However, overexpression of FoxM1 is closely associated with proliferation, metastasis, chemotherapy resistance and poor prognosis of various cancers. The correlation between its expression and tumorigenesis was first reported in basal cell carcinoma. In addition, the researchers obtained several groups of high-affinity peptides against the human FoxM1c-DBD protein expressed and purified from the bacterial system from the phage random twelve-peptide library. One of the novel binding peptides with high affinity for FoxM1c-DBD protein was conjugated with poly-Arg (D-9R) to enhance its penetration into the cell membrane and was named 9R-P. The results showed that 9R-P could strongly inhibit the viability, proliferation and migration of liver cancer HepG2 cells, and induce apoptosis by downregulating FoxM1 and regulating the expression of related genes in the signal transduction pathway. Therefore, 9R-P has great potential as a major anticancer drug targeting FoxM1.

[0006] Gas therapy (GT) has attracted much attention in cancer treatment in recent years. Gas therapy based on the in situ generation of gas molecules such as nitric oxide (NO), carbon monoxide (CO), hydrogen sulfide (H2S) and hydrogen (H2) has aroused great interest in tumor treatment. Similar to phototherapy, gas therapy also benefits from its excellent therapeutic effect and good biosafety. As a "star molecule" or "multi-effect molecule", NO can directly kill tumor cells by damaging DNA at high concentrations. NO can play a tumor-killing role at high concentrations (>1μM) by inducing mitochondrial / DNA damage and DNA damage, blocking DNA synthesis and repair, and inhibiting cellular respiration. In particular, inhibiting cellular respiration will save O2 to relieve hypoxia, which will improve the therapeutic effect of PDT. At low concentrations, NO can regulate the antioxidant effect of tumor cells and promote tumor survival and proliferation.

[0007] Although there are currently a variety of anti-tumor treatments, such as chemotherapy, photothermal therapy, photodynamic therapy, etc., a single treatment method without effective anti-tumor effects will still lead to problems such as multidrug resistance and postoperative recurrence. Therefore, the combination of multiple treatment methods such as gas therapy and photodynamic therapy has become a research hotspot.

[0008] Based on this, this application was developed. Summary of the invention

[0009] The purpose of the present invention is to overcome the defects of the prior art and provide a nano drug delivery system based on heat therapy, photodynamic therapy and gas therapy targeting liver cancer using a gold-silver alloy, which has the advantages of large drug loading capacity of nano drug carriers, high biosafety, small size, good water solubility, etc. The present invention introduces an innovative nano drug delivery system, which has important application value in the field of nano drug technology.

[0010] The present invention also provides a preparation method of the gold-silver alloy nano drug delivery system for targeting liver cancer based on thermal therapy, photodynamic therapy and gas therapy, and its application in the preparation of anticancer drugs. The present invention is a targeted nano delivery system for photothermal, photodynamic and gas therapy, in which the GNC itself has an excellent photothermal effect and the internal hollowness plays a role in transporting drugs; under the stimulation of laser irradiation, the photosensitizer ICG produces ROS to achieve photodynamic therapy and oxidizes L-arg to produce NO for gas therapy; the targeting polypeptide plays a role in transporting the nano delivery system to liver cancer cells, achieving the synergistic treatment of targeted photothermal, photodynamic and gas therapy for liver cancer.

[0011] In order to achieve the above-mentioned invention object, the present invention adopts the following technical scheme: A nano drug delivery system for liver cancer targeted by gold-silver alloy based on thermal therapy, photodynamic therapy and gas therapy, which consists of GNC, photosensitizer ICG loaded into GNC, gas diagnostic agent L-arg and peptide 9R-P modified on the surface of GNC. Among them, GNC has excellent photothermal conversion efficiency and plays the role of photothermal conversion, the photosensitizer ICG loaded inside GNC plays the role of photodynamic therapy, L-arg plays the role of gas therapy, and the outer modified targeting peptide 9R-P plays the role of active targeting of liver cancer cells. Under the action of the targeting peptide, the nano drug is accurately targeted to liver cancer cells and aggregates at the tumor cells. When laser irradiation is performed externally, GNC heats up at the tumor site to achieve the purpose of tumor ablation. The photosensitizer produces ROS to oxidize cells under light and oxidizes L-arg to produce NO to kill liver cancer cells. The entire nano delivery system combines photothermal, photodynamic therapy and gas therapy to achieve the effect of multi-modal combined therapy.

[0012] A method for preparing the above-mentioned gold-silver alloy nano drug delivery system targeting liver cancer based on thermal therapy, photodynamic therapy and gas therapy comprises the following steps: S1: Synthesis of silver nanocubes AgNC. The specific synthesis method is as follows: After heating an appropriate amount of ethylene glycol (EG) to 100-200°C in an oil bath, an ethylene glycol solution of sodium hydrosulfide (NaSH-EG) is quickly added; after waiting for 1-3 min, an ethylene glycol solution of polyvinyl pyrrolidone (PVP-EG) and an ethylene glycol solution of hydrochloric acid (HCl-EG, hydrochloric acid is calculated as HCl) are quickly added and stirred, and after waiting for 1-3 min, a polyethylene glycol solution of silver trifluoroacetate (CF3COOAg-EG) is added, and the reaction is closed and stirred for 1-2 h, and then the reaction is quenched with ice water, and a suspension containing AgNC (AgNC) is obtained after washing. The whole process needs to be carried out under light-proof conditions; the volume of the EG is 12-50 mL, specifically 25 mL; the heating temperature is 100-200°C, specifically 150°C; the concentration of NaSH-EG is 3 mM; the concentration of HCl-EG is 3 mM; the concentration of PVP-EG is 20 mg / mL; the concentration of CF3COOAg-EG is 282 mM; S2: Synthesis of hollow gold nanocages (GNCs): The AgNC-containing suspension obtained in the above step S1 is added to an aqueous solution containing an appropriate amount of polyvinyl pyrrolidone, and then slowly dripped with an aqueous solution of chloroauric acid and the UV absorption spectrum of the system is detected in time after heating in an oil bath to 50-150°C (preferably 90-110°C), until the maximum UV absorption peak of GNC is at 750-850 nm, the dripping is stopped, the ice water is quickly cooled to room temperature to stop the reaction, NaCl is added to form a supersaturated solution, centrifuged, washed, and a suspension containing GNC is obtained; the mass concentration of the AgNC-containing suspension is 0.25-1 mg / mL, specifically 0.5 mg / mL; the heating temperature is 50-150°C, specifically 100°C; the concentration of the aqueous solution of chloroauric acid is 1 mM. The overall particle size is 45-55 nm; S3: Preparation of GNCs loaded with ICG and L-arg (GNC@ICG / L-arg) and GNCs loaded with ICG (GNC@ICG): (a) The GNC-containing suspension obtained in S2 was diluted with deionized water, and then the photosensitizer ICG and the gas diagnostic agent L-arg were added at room temperature and in the dark, and stirred at room temperature for 12 to 36 h, centrifuged, and the obtained product GNC@ICG / L-arg (GIL) was collected; (b) The GNC-containing suspension obtained in S2 was diluted with deionized water, and the photosensitizer ICG was added to the suspension at room temperature in the dark and stirred for 12-36 h. The suspension was centrifuged to collect the obtained product GNC@ICG (GI).

[0013] S4: Preparation of GIL and GI modified with targeting peptide 9R-P: (a) The GNC@ICG / L-arg obtained in S3 (a) was dispersed in deionized water, and the targeting peptide 9R-P powder was added under slow stirring until fully dissolved. The mixture was stirred in the dark for 12-48 h and centrifuged to obtain the product GNC@ICG / L-arg@9R-P (GIL9R), which was stored in the dark for later use.

[0014] (b) The GNC@ICG obtained in S3 (b) was dispersed in deionized water, and the targeting peptide 9R-P powder was added under slow stirring until fully dissolved. The mixture was stirred in the dark for 12-48 h, centrifuged, and collected to obtain the product GNC@ICG@9R-P (GI9R).

[0015] Specifically, in step S1, the molar ratio of sodium hydrosulfide, HCl, and silver trifluoroacetate is 1:7-10:600-650, and 120-150 mg of polyvinyl pyrrolidone is added for every 0.001 mmol of sodium hydrosulfide. Preferably, NaSH-EG, HCl-EG, and CF3COOAg-EG can be added at a molar concentration ratio of 1:0.5-2:90-100, and the mass concentration of PVP-EG can be 15-25 mg / mL.

[0016] Specifically, in step S2, the mass ratio of AgNC to polyvinyl pyrrolidone is 1:25-30. The mass concentration of the aqueous solution of polyvinyl pyrrolidone can be 1-2 mg / mL, and the molar concentration of the aqueous solution of HAuCl4 can be 0.5-2 mM.

[0017] Furthermore, in step S3 (a), the mass ratio of GNC to photosensitizer ICG and gas diagnostic agent L-arg is 1:1-3:1-3, preferably 1:2:2; in step S3 (b), the mass ratio of GNC to photosensitizer ICG is 1:1-3, preferably 1:2.

[0018] Furthermore, in step S4 (a) and (b), the mass ratio of GNC@ICG / L-arg to targeting peptide 9R-P is 1:0.4-2, preferably 1:0.5.

[0019] Further preferably, in step S4, the sequence of the targeting polypeptide 9R-P is: RRRRRRRRRGSGSWHLDYPSMWYLD.

[0020] The present invention also provides the use of the above-mentioned gold-silver alloy nanodrug delivery system targeting liver cancer based on thermal therapy, photodynamic therapy and gas therapy in the preparation of anti-cancer drugs, that is, the use of the gold-silver alloy nanodrug delivery system targeting liver cancer based on thermal therapy, photodynamic therapy and gas therapy in gas therapy, photothermal therapy and photodynamic therapy combined with anti-liver cancer treatment.

[0021] The nano drug delivery system of gold-silver alloy targeting liver cancer based on heat therapy, photodynamic therapy and gas therapy of the present invention can realize the synergistic reaction of photosensitive ICG and L-arg to improve the gas therapy effect. The nano drug delivery system uses GNC as a carrier to load the drug into the interior, and actively targets the tumor tissue in the body under the protection of the outer layer polypeptide, especially the internal circulation, to form a nano delivery system for multi-mode combined treatment of photodynamic therapy, gas therapy and photothermal therapy. In short, GNC, as a good photothermal material and carrier, plays a key role in the photothermal effect. The loaded photosensitizer can not only produce reactive oxygen but also oxidize L-arginine to generate NO for gas therapy, effectively inhibiting the growth of tumors. At the same time, the outer layer of the polypeptide can avoid drug leakage on the one hand, and actively target the tumor tissue on the other hand to exert the excellent anti-liver cancer treatment effect of the nano delivery system, realizing the triple combined treatment of active targeted photothermal therapy, photodynamic therapy and gas therapy for liver cancer. That is, the present invention provides a new nano drug delivery system that can realize photothermal therapy, photodynamic therapy and gas therapy for liver cancer, and can achieve a more efficient targeted liver cancer treatment effect.

[0022] The present invention loads ICG and L-arg into the GNC, which can greatly promote the efficient synergistic effect of photodynamic therapy and gas therapy under near-infrared light stimulation. Compared with the prior art, the gold-silver alloy nano drug delivery system for targeting liver cancer loaded with L-arg and ICG of the present invention has the following advantages and beneficial effects: 1) The present invention uses L-arg, photosensitizer ICG, polypeptide 9R-P and GNC as raw materials to obtain a gold-silver alloy nano drug delivery system targeting liver cancer. The raw materials used in the present invention are basically non-toxic and have excellent biocompatibility.

[0023] 2) The photosensitizer indocyanine green in the present invention can not only be used for photodynamic therapy, but also can oxidize L-arg to produce NO for gas therapy, achieving the effect of "killing two birds with one stone".

[0024] 3) The present invention encapsulates the polypeptide 9R-P that can actively target the FOMX1 receptor of liver cancer cells, and can accurately deliver the nano-delivery system to liver cancer tissue.

[0025] 4) The present invention has the characteristics of simple operation, high safety, controllable reaction process and low cost. The prepared gold-silver alloy nanodrug delivery system for targeting liver cancer loaded with L-arginine (L-arg) and indocyanine green has good hydrophilicity, small size, good dispersibility, high biosafety, and low reagent toxicity during the preparation process. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1Transmission electron microscopy (TEM) images of (a) AgNC, (b) GNC, (c) GIL, (d) GIL9R in Example 1, and (e) bright field, elemental mapping images of Au, Ag, C, and N in GIL9R; Figure 2 is the UV absorption graph of AgNC, GNC, GIL, GIL9R, ICG, and L-arg in Example 1; Figure 3 (a) particle size and (b) zeta potential of AgNC, GNC, GIL, and GIL9R in Example 1; Figure 4 The infrared spectra of L-arg, GNC, and GNC@ICG / L-arg in Example 1; Figure 5 is the EDS map of GIL9R; Figure 6 (a) is the GIL9R of the present invention under 808 nm laser (1.5 W / cm 2 (a) is the temperature change of the product GIL9R100 μg / mL under 808 nm laser irradiation for 10 min at different powers; Figure 7 The laser (808 nm, 1.5 W / cm 2 ) Temperature changes during 5 laser on / off cycles; Figure 8 (a) Hemolysis experiment picture and (b) hemolysis rate graph of GIL9R in Example 1; Fig. 9 The results of the laser irradiation toxicity test of GIL9R and GIL9R+L on (a) HepG2, (b) HeLa, and (c) SNU-739 cells in Example 1 are shown; Fig.10 Example 1 PBS, ICG, GIL9R at different concentrations under laser (808 nm, 1.5 W / cm 2 )Irradiated for 10 min (a) Infrared thermal imaging image; (b) Corresponding temperature change image; Fig.11 The present invention shows the GIL9R effect on (a) mouse tumor trend graph; (b) mouse tumor weight graph; (c) mouse body weight trend graph; (d) mouse tumor size trend graph. DETAILED DESCRIPTION

[0027] In order to further understand the present invention, the present invention is further described below in conjunction with the accompanying drawings and specific implementation methods. However, it should be understood that these descriptions are only for further illustrating the features and advantages of the present invention rather than limiting the scope of protection of the present invention.

[0028] Experimental instrument name and model: American Perkin-Elmer Lambda-850 UV spectrophotometer; VERTEX 70 Fourier transform infrared spectrometer from Bruker, Germany; BioTek multifunctional microplate reader from the United States; Japan JEOL JEM-200CX transmission electron microscope; NanoZS90 laser particle size and Zeta potential tester from Malvern, UK; American FLUKE TiS75+ handheld thermal imager.

[0029] In the following examples, the raw materials used are all common commercial products that can be directly purchased or can be prepared using conventional techniques in the art.

[0030] Unless otherwise specified, the solvent was water and the room temperature was 25±5℃.

[0031] Example 1 A method for preparing the above-mentioned gold-silver alloy nano drug delivery system targeting liver cancer based on thermal therapy, photodynamic therapy and gas therapy comprises the following steps: S1 Synthesis of silver nanocubes AgNC At room temperature, add 25 mL of EG to a round-bottom flask and place it in an oil bath. Preheat to 150°C, then quickly add 0.3 mL of NaSH-EG (3mM), quickly add 6.25 mL of PVP-EG (20 mg / mL) and 2.5 mL of HCl-EG (3mM) 2 min later, slowly add 2 mL of CF3COOAg-EG (282mM) 2 min later, and finally seal with a glass stopper. Stir the reaction for 90 min, then quickly quench the reaction with ice water, add about 2 times the volume of acetone and mix evenly. Centrifuge at 8000 rpm / min for 10 min, and discard the supernatant. After resuspending with deionized water, centrifuge and wash 3 times at 8000 rpm / min for 10 min to obtain a suspension containing 25 mg of silver nanocubic liquid (AgNC), which is diluted to 50 mL for use. The whole process needs to be carried out under light-proof conditions.

[0032] S2 Synthesis of hollow gold nanocages (GNCs) Take 10 mL of the suspension containing AgNC obtained in step S1 above, add it to 90 mL of PVP aqueous solution (1.5 mg / mL) and stir evenly, place it in a 100℃ oil bath to preheat for 10 min, and after reaching the temperature, slowly add 1mM HAuCl aqueous solution using a syringe and detect the ultraviolet absorption spectrum of the system in time until the maximum ultraviolet absorption peak of the gold nanocage GNC is around 800 nm. Stop adding. The ice water is quickly cooled to room temperature to stop the reaction. Then NaCl is added to make the system a supersaturated solution, and finally centrifuged at 1000 rpm / min for 10 min and washed twice with deionized water to obtain a suspension containing 2.5 mg of gold nanocages (GNC) for use.

[0033] S3 Preparation of GNCs loaded with ICG and L-arg (GNC@ICG / L-arg, GIL) and GNCs loaded with ICG (GNC@ICG, GI): (a) The suspension containing 2.5 mg of gold nanocages (GNC) obtained in step S2 above was diluted with deionized water to prepare a 1 mg / mL solution, and 1.25 mL of the previously prepared indocyanine green aqueous solution (4 mg / mL) and 1.25 mL of the L-arg aqueous solution (4 mg / mL) were added at room temperature in the dark. After ultrasonication for 15 min, the mixture was stirred at room temperature in the dark for 24 h, centrifuged, and 2.5 mg of the product GNC@ICG / L-arg (GIL) was collected.

[0034] (b) The suspension containing 2.5 mg of gold nanocages (GNC) obtained in step S2 was diluted with deionized water to prepare a 1 mg / mL solution, and 1.25 mL of the previously prepared indocyanine green aqueous solution (4 mg / mL) and 1.25 mL of deionized water were added at room temperature in the dark. After ultrasonication for 15 min, the mixture was stirred at room temperature in the dark for 24 h, centrifuged, and 2.5 mg of the product GNC@ICG (GI) was collected.

[0035] S4 Preparation of liver cancer targeting peptide-modified GIL (GNC@ICG / L-arg@9R-P, GIL9R) ​​and GI (GNC@ICG@9R-P, GI9R) (a) The GIL obtained in step S3 (a) above was dispersed in deionized water to prepare a solution with a concentration of 0.4 mg / mL (the solution was evenly dispersed by ultrasound), and then 1.25 mg of the targeting peptide 9R-P (sequence: RRRRRRRRRGSGSWHLDYPSMWYLD, purchased from Shanghai Qiangyao Biotechnology Co., Ltd.) was added under slow stirring. After the powder was fully dissolved, it was stirred at room temperature in the dark for 24 h and centrifuged to obtain the product GNC@ICG / L-arg@9R-P (GIL9R), which was stored in the dark for later use.

[0036] (b) The GI obtained in step S3 (b) was dispersed in deionized water to prepare a solution with a concentration of 0.4 mg / mL (evenly dispersed by ultrasound), and then 1.25 mg of the targeting peptide 9R-P (sequence: RRRRRRRRRGSGSWHLDYPSMWYLD, purchased from Shanghai Qiangyao Biotechnology Co., Ltd.) was added under slow stirring. After the powder was fully dissolved, it was stirred at room temperature in the dark for 24 h and centrifuged to obtain the product GNC@ICG@9R-P (GI9R), which was stored in the dark for later use.

[0037] The AgNC, GNC, GIL and GIL9R in Example 1 were characterized by transmission electron microscopy (TEM). Figure 1 .from Figure 1 It can be observed that: (a) is AgNC, which has a square shape and a solid interior; (b) is GNC, which has a hollow interior and can be used for drug loading; (c) is GIL, and the morphology of the gold nanocage does not change after loading ICG and L-arg; (d) is GIL9R, and after modification with the targeting peptide, a thin film is attached to the outer layer, indicating the successful modification of the targeting peptide; (e) is the mapping diagram of GIL9R, from left to right are the element mappings of bright field, Au, Ag, C, and N. It can be seen that the signal evenly passes through the selected area of ​​the sample, further confirming the successful synthesis of GIL9R.

[0038] The nano drug delivery system was scanned at full wavelength using UV-NIR absorption spectroscopy. Figure 2 ; Figure 2 is the ultraviolet absorption peak spectrum of AgNC, GNC, GIL, GIL9R, ICG and L-arg in Example 1 of the present invention. Figure 2 It can be seen that after AgNC is etched and transformed into GNC, the ultraviolet absorption peak also red-shifts from 430 nm to 790 nm; after loading ICG and L-arg, the ultraviolet absorption peak of GNC at 780 nm corresponds to the ultraviolet absorption peak of ICG, indicating the successful loading of the drug and that the morphology of GNC is not affected after loading the drug.

[0039] The Zeta potential, water content and particle size of AgNC, GNC, GIL and GIL9R were tested using a Zeta potential meter. The results are shown in Figure 3 .Depend on Figure 3 (a) shows that the particle size of AgNC after synthesis is 51.65±1.3 nm. After the replacement reaction, the hollow GNC is obtained, and its particle size reaches 96.21±4.9 nm, which further shows that the GNC is successfully prepared. After loading the drug, its particle size does not change much, which is 122.4±7.5 nm, which also shows that the drug is successfully loaded into the GNC. Since 9R-P is a macromolecular substance, the particle size becomes 209.1±10.7 nm after coating GIL, which shows that 9R-P is successfully loaded. Figure 3 It can be seen in (b) that the GNC obtained by the replacement reaction of AgNC still has a negative potential (-30±0.5 mV); since the isoelectric point of L-arginine is 10.76, it has a positive potential in aqueous solution, ICG has a negative potential in the solution, and finally GIL has a negative potential in the solution (-43.2±-0.9 mV); the targeting peptide 9R-P has a strong positive charge, so GIL9 shows a positive potential (29.8±1.4 mV).

[0040] Fourier transform infrared spectrometer was used to analyze the infrared spectra of L-arg, GNC, and GNC@ICG / L-arg. The results are shown in Figure 4 .like Figure 4 Shown: L-arg at 1562.26 cm -1 The NH bending vibration absorption peak is emitted by L-arg. The above peak still exists in GNC@L-arg and GNC@ICG / L-arg, but it is much weaker in comparison, which also indirectly indicates the successful loading of L-arg.

[0041] The elements of GIL9R were analyzed by EDS using a transmission electron microscope. The results are shown in Figure 5 . Figure 5 It can be seen that the sample mainly contains Au, Ag, C, and N elements, which provides a basis for the successful synthesis of GNC.

[0042] The GIL9R prepared by the present invention is irradiated with a 808 nm semiconductor laser. Figure 6 When the concentration of GIL9R was 100 μg / mL and the power was different (0.25 W / cm 2 , 0.75 W / cm 2 , 1.5 W / cm 2 , 2 W / cm 2 , 2.5W / cm 2After being irradiated by laser for 10 min, the temperature changes as follows: Figure 6 (b) As shown in the figure, the temperature increases with the increase of power, indicating that GIL9R has excellent photothermal performance. The product GIL9R was prepared with ultrapure water at different concentrations (PBS, 25 μg / mL, 50 μg / mL, 100 μg / mL, 200 μg / mL) and then exposed to laser (808 nm, 1.5 W / cm 2 ) for 10 min. Figure 6 As shown in (a), Figure 6 (a) It can be seen that different concentrations of GIL9R under 1.5 W / cm 2 After 10 min of irradiation, the higher the concentration, the faster the temperature rises, and the temperature also increases with the increase of concentration, and finally rises to 41.4℃, 44.7℃, 48.9℃, and 51.8℃, respectively, while the blank control group (PBS) only rose to 35.8℃, indicating that GIL9R has good photothermal conversion ability. The above experiments show that the photothermal performance of gold nanocages is not affected by drug loading, which further verifies the excellent photothermal performance of GIL9R.

[0043] Figure 7 The photothermal stability of GIL9R (100 μg / mL) was further evaluated. GIL9R was exposed to (808 nm, 1.5 W / cm 2 ) 5 times of laser on / off irradiation, turn off after reaching the highest temperature value, and cool naturally to room temperature. From the beginning, record the temperature every 30 s, and draw a curve of its temperature change with laser irradiation time and natural cooling time. Figure 7 It can be seen that GIL9R still has a good heating effect. Figure 6 The experimental results are consistent with .

[0044] The present invention also conducted a hemolysis experiment of GIL9R to prove the biosafety of the nanomedicine: different concentrations of GIL9R (100 μg / mL, 200 μg / mL, 300 μg / mL, 400 μg / mL, 500 μg / mL, 600 μg / mL) were prepared using red blood cell suspensions, and red blood cell suspensions prepared with physiological saline were used as negative control groups, and red blood cell suspensions containing ultrapure water were used as positive control groups. The OD value of hemoglobin in the supernatant at 540 nm was determined by a multifunctional microplate reader.

[0045] If the hemolysis rate of GIL9R at the set concentration is less than 5%, GIL9R has no hemolytic effect at the maximum concentration and can be used for subsequent animal intravenous injection. Figure 8 As shown in the figure, the hemolysis rate of GIL9R at the maximum concentration of 600 μg / mL was still less than 5%, indicating that the biosafety of the entire system was high and could be used for intravenous administration.

[0046] Fig. 9 The toxicological test results of GIL9R and GIL9R+L in the present invention after irradiation of (a) HepG2, (b) HeLa, and (c) SNU-739 cells with 808 nm laser for 5 minutes. It can be seen from the figure that: without laser irradiation, GIL9R has basically no toxic side effects on HepG2, HeLa, and SNU-739; due to the presence of FoxM1 receptors specifically recognized by 9R-P peptide on the surface of HepG2, after adding laser treatment (GIL9R+L), Fig. 9 The data obtained in the calculation formula were obtained: IC of GIL9R on HepG2 50 The IC values ​​for HeLa and SNU-739 were 6.79 μg / mL. 50 The concentrations of GIL9R in HepG2 cells were 15.97 μg / mL and 10.12 μg / mL respectively. The therapeutic effect of GIL9R on HepG2 cells was better than that on HeLa and SNU-739 cells. This further verified that GIL9R has excellent anti-liver cancer effects.

[0047] Fig.10 The infrared thermal imaging (a) and temperature change (b) of the tumor tissue of BALB / c mice of GIL9R under laser irradiation of the present invention. GIL9R with a concentration of 100 μg / mL was irradiated by laser (808 nm, 1.5 W / cm 2 ) irradiation, the temperature of the tumor tissue gradually increased with time, indicating that GIL9R still has excellent photothermal properties in mice.

[0048] Fig.11 In order to evaluate the anti-tumor effect of GIL9R in mice in the present invention, we divided H22 tumor-bearing mice into 7 groups, namely PBS group, GIL group, GIL+L group, GI9R group, GI9R+L group, GIL9R group, and GIL9R+L group. During the treatment period, PBS group, GIL group, GIL+L group, GI9R group, GI9R+L group, GIL9R, and GIL9R+L group were all prepared with PBS (pH 7.4) buffer solution to the required concentration. The dosage of nanomedicine in each group was 5 mg / kg, and it was injected into the body through the tail vein of mice. Among them, the GIL+L group, GI9R+L group, and GIL9R+L group needed to use an 808 nm laser (1.5 W / cm 2The whole treatment cycle lasted for 14 days. The tumor size and weight of mice in each group were measured and recorded every 24 hours. The results are shown in Fig.11 . Fig.11 In (a), it can be seen that after laser irradiation, the tumors of both the GIL+L group and the GIL9R+L group were significantly reduced, but the tumor reduction in the GIL9R+L group was particularly significant, indicating the significant effect of the GIL9R+L combination therapy; the GIL group had an inhibitory effect on tumors when it was not connected to the targeting peptide 9R-P, but there was no significant difference compared with the blank control group. After the GIL9R+L group was connected to the targeting peptide, it was able to achieve the best tumor killing effect, indicating that the final system of nanomedicine can actively target tumor cells and can effectively inhibit the proliferation of tumor cells. Fig.11 (b) It can be seen that: there is no significant difference in the tumor weight of mice in the GIL group, GI9R group, and GIL9R group; the tumor weight of the GI9R+L group and the GIL+L group was significantly reduced compared with that of the GIL9R+L group, and the difference was obvious. Fig.11 In (c), although there are slight differences in the body weights of mice in each group, this may be due to the breeding environment and weather temperature, and can be ignored. Fig.11 (d) is a graph of mouse tumor size, showing that GIL9R+L can achieve very significant anti-tumor effects after adding multimodal treatment. This further verifies that the GIL9R+L group can achieve the best tumor inhibition effect under laser irradiation conditions.

[0049] In summary, the nanodrug delivery system based on gold-silver alloy targeting liver cancer described in the present invention has stable properties and good biocompatibility. It combines ICG for photodynamic therapy and L-arginine for gas therapy, and combines with GNC's photothermal therapy to actively target liver cancer to achieve a multimodal treatment effect and has excellent therapeutic effects on liver cancer. It has a good application prospect in the study of the active targeted anti-cancer activity of nanodrug carriers.

Claims

1. A nano drug delivery system targeting liver cancer based on gold-silver alloy based on thermal therapy, photodynamic therapy and gas therapy, characterized in that: It consists of GNC, photosensitizer ICG and gas diagnostic agent L-arg loaded into the interior of GNC, and polypeptide 9R-P modified on the surface of GNC.

2. The method for preparing the gold-silver alloy nano drug delivery system targeting liver cancer based on thermal therapy, photodynamic therapy and gas therapy according to claim 1, characterized in that: The steps include: S1: Synthesis of Silver Nanocubes AgNC: After heating an appropriate amount of ethylene glycol to 100-200°C, add an ethylene glycol solution of sodium hydrosulfide; after 1-3 min, add an ethylene glycol solution of polyvinyl pyrrolidone and an ethylene glycol solution of hydrochloric acid; after waiting for 1-3 min, add a polyethylene glycol solution of silver trifluoroacetate; after stirring in a closed chamber for 1-2 h, quench the reaction with ice water, and wash to obtain a suspension containing AgNC; S2: Synthesis of hollow gold nanocages (GNCs): The AgNC-containing suspension obtained in the above step S1 is added to an aqueous solution containing an appropriate amount of polyvinyl pyrrolidone, heated to 50-150°C, and then an aqueous solution of chloroauric acid is added and the ultraviolet absorption spectrum of the system is detected in due time until the maximum ultraviolet absorption peak is at 750-850nm, and then the reaction is stopped by cooling the ice water to room temperature, and NaCl is added to form a supersaturated solution, and then centrifuged and washed to obtain a GNC-containing suspension; S3: Preparation of ICG and L-arg loaded GNCs: The GNC-containing suspension obtained in S2 was diluted with deionized water, and then the photosensitizer ICG and the gas diagnostic agent L-arg were added at room temperature and stirred in the dark for 12 to 36 h, and the obtained product GNC@ICG / L-arg was collected; S4: Preparation of GIL modified with targeting peptide 9R-P: The GNC@ICG / L-arg obtained in S3 was dispersed in deionized water, and the targeting peptide 9R-P powder was added under stirring. The mixture was stirred in the dark for 12-48 h and centrifuged to obtain the product.

3. The method for preparing the gold-silver alloy nano drug delivery system targeting liver cancer based on thermal therapy, photodynamic therapy and gas therapy as claimed in claim 2, characterized in that: In step S1, the molar ratio of sodium hydrosulfide, HCl and silver trifluoroacetate is 1:7-10:600-650, and 120-150 mg of polyvinyl pyrrolidone is added for every 0.001 mmol of sodium hydrosulfide.

4. The method for preparing the gold-silver alloy nano drug delivery system targeting liver cancer based on thermal therapy, photodynamic therapy and gas therapy as claimed in claim 2, characterized in that: In step S2, the mass ratio of AgNC to polyvinyl pyrrolidone is 1:25-30.

5. The method for preparing the gold-silver alloy nano drug delivery system targeting liver cancer based on thermal therapy, photodynamic therapy and gas therapy as claimed in claim 2, characterized in that: In step S3, the mass ratio of GNC to photosensitizer ICG and gas diagnostic and therapeutic agent L-arg is 1:1-3:1-3.

6. The method for preparing the gold-silver alloy nano drug delivery system targeting liver cancer based on thermal therapy, photodynamic therapy and gas therapy as claimed in claim 2, characterized in that: In step S4, the mass ratio of GNC@ICG / L-arg to targeting peptide 9R-P was 1:0.4~2.

7. The method for preparing the gold-silver alloy nano drug delivery system targeting liver cancer based on thermal therapy, photodynamic therapy and gas therapy as claimed in claim 5, characterized in that: In step S4, the sequence of the targeting polypeptide 9R-P is: RRRRRRRRRGSGSWHLDYPSMWYLD.

8. Use of the gold-silver alloy nanodrug delivery system targeting liver cancer based on thermal therapy, photodynamic therapy and gas therapy as claimed in claim 1 in the preparation of anticancer drugs.

Citation Information

Cited By

  • Fullerene composite silver nanoparticles capable of producing nitric oxide as well as preparation method and application of fullerene composite silver nanoparticles

    CN119819918A

  • IR820-GPC3-Gd compound for liver cancer light diagnosis and treatment and magnetic resonance imaging and nano material, preparation method and application of IR820-GPC3-Gd compound

    CN120590478A